high-risk
AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients
Imfinzi, Clinical Trials, high-risk, expansion, Malignant neoplasm of urinary bladder
KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer
KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024